Should I buy Merck & Co. Inc. (MRK)?

What Hold means for MRK today

A Hold rating is the output of the composite fair-value band ($94.9–$147) compared with the live price ($112), a 9/10 moat score, and a 84/100 confidence reading on the data quality and model convergence behind the fair-value range. We do not issue Buy / Strong Buy unless valuation is in the strong half of our six-factor decision overlay AND the risk profile is non-elevated; the rating is gated, not free-form.

Hold. Current price of $112.30 represents limited upside of 7.4% to our $120.61 fair value mid-point, appropriately pricing in the pipeline transition risks. The full report explains every input: discount rate, terminal growth, deceleration curve, scenario probabilities, and where the rating could change next.

Bull, base and bear over our base horizon

Bull case (probability 20%): target $146.75, return +30.7%. Base case (probability 60%): target $120.61, return +7.4%. Bear case (probability 20%): target $94.87, return -15.5%.

Probability weights are not symmetric. Merck & Co. Inc. is a mature-dividend stock, so the deceleration curve, terminal P/E, and confidence in the bull tail are calibrated to that archetype. The probability-weighted expected value in the full report folds these three scenarios into a single asymmetric expected return — a more honest "should I buy?" signal than any single point estimate.

Risks to the thesis

The top kill-scenarios our latest report flags for Merck & Co. Inc. are: Severe Keytruda Cliff; ADC Pipeline Failure; Draconian IRA Pricing. The single biggest risk is Severe Keytruda Cliff: Failure to offset Keytruda LOE through M&A or internal ADC pipeline leaves a massive revenue gap, severely compressing structural margins.

The biggest opportunity is Bull: Successful clinical outcomes for late-stage ADC candidates and continued label expansions for current assets fully offset the 2028 Keytruda loss of exclusivity. This drives steady single-digit revenue growth and supports continued dividend expansion. Position management in the full report converts the rating into concrete checkpoints — quarterly reassessment triggers and the metric thresholds that should change the size of the position rather than the position itself.

Bottom line

Our Hold rating with 84/100 confidence is research for educational purposes — not personalised investment advice and not a price call. Use the fair-value range and the bull/base/bear distribution to size a view; use the kill-scenarios and the earnings decision tree to define what would invalidate it.

For the full evidence — 14 sections, sensitivity grid, scorecard, and the data-provenance appendix — see the canonical report at /stocks/mrk/analysis.

Frequently asked questions